This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
First Tracks Biotherapeutics Inc TRAX
$34.42
▼ -3.94%
($-1.41)
Open
$35.82
Prev Close
$35.83
Day Range
$33.66 – $35.82
52W Range
$14.72 – $49.91
Market Cap
$1.23B
Beta
1.71
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-04-06 |
| Shares Out. | 34,890,000 |
| Website | firsttracksbio.com ↗ |
| Phone | 12123733000 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$33.4M |
| Total Assets | $183.1M |
| Total Liabilities | $14.3M |
| Equity | $168.8M |
About First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
First Tracks Biotherapeutics Inc is a publicly traded company under the ticker symbol TRAX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)